4933428G09Rik Activators
4933428G09Rik activators encompass a diverse array of chemical compounds that bolster the protein's activity through intricate signaling pathways. Forskolin and IBMX elevate intracellular cAMP, subsequently activating PKA, which may phosphorylate and augment proteins in the 4933428G09Rik-associated pathways, thus enhancing its function. Similarly, Genistein's inhibition of tyrosine kinases may reduce competition for 4933428G09Rik pathways, indirectly upholding its activity. The activation of protein kinase C by PMA could also facilitate the phosphorylation of substrates within the 4933428G09Rik pathways, leading to increased functional activity. Compounds such as LY294002 and U0126, by inhibiting PI3K and MEK1/2 respectively, may shift signaling dynamics to favor 4933428G09Rik activity. Moreover, SB203580's inhibition of the p38 MAPK could alleviate suppressive effects on the protein's pathways, while sphingosine-1-phosphate engages G-protein coupled receptors, which may amplify 4933428G09Rik signaling.
The functional landscape of 4933428G09Rik is further sculpted by modulators of intracellular calcium and kinase activity. A23187, by increasing intracellular calcium levels, activates calcium-dependent pathways that could intersect with and enhance the functional repertoire of 4933428G09Rik. Epigallocatechin gallate and Staurosporine, both kinase activity modulators, may fine-tune the signaling milieu to favor 4933428G09Rik activity, the former by potentially reducing competitive substrate phosphorylation and the latter by selectively relieving inhibition on relevant pathways. Thapsigargin's role in elevating cytosolic calcium levels, through SERCA pump inhibition, offers another route to potentiate 4933428G09Rik's activity by engaging calcium-sensitive signaling cascades. These chemical entities, through their targeted modulation of signaling processes, collectively underpin the enhancement of 4933428G09Rik's function in its native cellular context without necessitating direct activation or overexpression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX acts as a non-specific inhibitor of phosphodiesterases, which increases cAMP by preventing its breakdown. This elevated cAMP can activate PKA, which in turn may enhance the activity of 4933428G09Rik through phosphorylation of proteins in related signaling pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, may allow for pathways involving the 4933428G09Rik protein to be more active by inhibiting competing tyrosine kinase signaling pathways, which can indirectly increase 4933428G09Rik activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is an activator of protein kinase C (PKC), which can phosphorylate substrates and potentially enhance signaling pathways that include 4933428G09Rik, leading to its functional activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter downstream signaling, potentially reducing negative regulatory influences on pathways involving 4933428G09Rik, which could result in an enhanced functional activity of the protein. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, which could relieve inhibitory control on pathways in which the 4933428G09Rik protein is involved, potentially enhancing its functional activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate is involved in signaling that can lead to the activation of G-protein coupled receptors and downstream kinases, which may intersect with the signaling pathways of 4933428G09Rik, resulting in enhanced activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore, raising intracellular calcium levels and activating calcium-dependent signaling pathways that could intersect with and enhance the activity of 4933428G09Rik. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate, a kinase inhibitor, might reduce competitive signaling, potentially allowing for greater activity of pathways involving 4933428G09Rik, thus enhancing its function. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a broad-spectrum protein kinase inhibitor, might selectively enhance pathways associated with 4933428G09Rik by lifting inhibition on these specific pathways, despite its general kinase inhibition. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the SERCA pump, leading to increased cytosolic calcium levels, which can activate calcium-dependent signaling pathways that may enhance the activity of 4933428G09Rik. | ||||||